/First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Citation Map
The articles shown here are a subset.See the full list of articles below.
Citing (0)
Citation Count
Cited By (0)
Citation Count